Result of General Meeting
Biodexa Pharmaceuticals PLC
Result of General Meeting
Biodexa Pharmaceuticals PLC ('Biodexa' or the 'Company') (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces, announces that at its General Meeting held earlier today, all four resolutions put to the Company's shareholders were duly passed.
The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting and General Meeting can be found in the Notice of the General Meeting on the Company's website at: https://biodexapharma.com/investors/corporate-governance/#agms.
The effect of resolutions 1 and 4 is solely to reduce the nominal, or par, value per ordinary share. There is no change to the number of ordinary shares outstanding.
The effect of resolutions 2 and 3 is to grant the Directors the authority to allot ordinary shares on a non-pre-emptive basis.
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa's headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking StatementsCertain statements in this announcement may constitute 'forward-looking statements' within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not anticipate', or 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved.' Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
First Solar Stock Jumps After Q2 Beat and Raised Full-Year Outlook
Aug 1 - First Solar (NASDAQ:FSLR) gained 6.5% on Friday afternoon after posting second?quarter results that topped Wall Street expectations and prompted the solar manufacturer to raise its full?year guidance. Warning! GuruFocus has detected 5 Warning Signs with FSLR. The company reported Q2 net income of $341.9 million, or $3.18 per share, compared with $349.4 million, or $3.25 per share, a year ago. Analysts surveyed by FactSet expected $2.66 per share. Revenue climbed to $1.1 billion from $1.01 billion a year earlier, driven by higher sales of solar modules to third?party customers. Management now projects 2025 revenue between $4.9 billion and $5.7 billion, up from a prior $4.5 billion to $5.5 billion. Earnings guidance tightened to $13.50$16.50 per share, versus the earlier $12.50$17.50 range. First Solar also raised the lower end of its full?year solar module shipment target to 16.719.3 GW and adjusted its gross margin outlook to $2.05$2.35 billion. CEO Mark Widmar said the company benefits from President Trump's recently enacted tax law, which favors U.S.?made solar panels while limiting credits tied to Chinese supply chains. Analysts note that ongoing trade and tariff uncertainty still poses challenges but may also create opportunities for domestic manufacturers. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Moderna Cuts Forecast, Stock Wobbles Despite Beat
Moderna's (NASDAQ:MRNA) quarter was okay on the numbers, but the stock slid because the company pulled back its full-year revenue outlook after delaying some U.K. vaccine shipments into early 2026. Q2 revenue was $142Million, down 41% from a year ago, with COVID shot sales at $114Million and its RSV vaccine barely registering. That pushed the 2025 revenue range to $1.5Billion$2.2Billion, about $300Million less than before. Warning! GuruFocus has detected 2 Warning Sign with MRNA. The good part is they've been cutting costs aggressively. OpEx is now guided to $5.9Billion$6.1Billion roughly $400Million lighter than prior expectationsand that helped trim the loss to about $800Million. Moderna still has a strong cash cushion: $7.5Billion at the end of June and roughly $6Billion expected at year-end, so the balance sheet isn't stressed. The delayed shipments rattled sentiment, but the company isn't burning cash. Now it comes down to executionU.K. deliveries must land as rescheduled and new revenue drivers need to show up before investors lose patience. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
24 minutes ago
- Business Wire
SITE Centers Announces Two Sales and Special Common Distribution
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC) announced today the sale of Winter Garden Village (Orlando, FL) for $165.0 million and the sale of Deer Valley Towne Center (Phoenix, AZ) for $33.7 million, both prior to closing costs, prorations and other closing adjustments. A portion of net proceeds were used to repay $22.3 million of mortgage debt. The Company's Board of Directors also declared a special cash distribution on its common shares of $3.25 per common share payable on August 29, 2025 to shareholders of record at the close of business on August 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company's common shares, NYSE has advised the Company that its common shares will trade with 'due bills' representing an assignment of the right to receive the special dividend from the record date of August 15, 2025 through the closing of trading on NYSE on August 29, 2025, which is the payment date and the last day of trading before the September 2, 2025 ex-dividend date (this period of time representing the 'Dividend Right Period'). Shareholders who sell their common shares during the Dividend Right Period will be selling their right to the special dividend, and such shareholders will not be entitled to receive the special dividend. Due bills obligate a seller of common shares to deliver the special dividend payable on such common shares to the buyer (the 'Dividend Right'). The record date of August 15, 2025 will be used as the date for establishing the due bill tracking of the Dividend Right to the holder of common shares. Due bill obligations are customarily settled between the brokers representing the buyers and the sellers of shares. The Company has no obligation for either the amount of the due bill or the processing of the due bill. Buyers and sellers of the Company's common shares should consult their brokers before trading to be sure they understand the effect of NYSE's due bill procedures. About SITE Centers Corp. SITE Centers is an owner and manager of open-air shopping centers located primarily in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC. Additional information about the Company is available at To be included in the Company's e-mail distributions for press releases and other investor news, please click here.
